Business Wire

Chugai Releases Disease Awareness Anime about Rheumatoid Arthritis in Multiple Languages Emphasizing Importance of Early Detection/Treatment and Care by Specialists

Jaa

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that it released a disease awareness anime about rheumatoid arthritis dubbed in English and subtitled in Chinese, Korean, French and Spanish, celebrating World Arthritis Day on October 12.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181011005989/en/

(Graphic: Business Wire)

(Graphic: Business Wire)

Rheumatoid arthritis is an autoimmune disease that most commonly develops in women aged from 30 to 59. The number of patients is estimated to be 0.7 million in Japan and 23 million in the world*. The disease causes destruction of the joints and bones and deformation of hands and feet, which may significantly affect daily lives. However, with recent treatment advances an increasing number of people with the disease can control joint swelling and pain, as well as continue daily activities like housekeeping and hobbies, if they visit specialized medical centers early and receive appropriate treatment.
*Report by Study Committee on Rheumatoid Arthritis and Allergy; (http://www.mhlw.go.jp/stf/houdou/2r9852000001nfao-att/2r9852000001nfdx.pdf) and WHO Global Burden of Disease Report (table 7, page 32) 2004; (http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf)

Chugai has continuously emphasized the importance of early treatment of rheumatoid arthritis and promoted a better understanding through a short film titled “Mother’s Lipstick” (awarded 2016 Cannes Lions Bronze) and a music video titled “With A Wish” released by a singer, Mina Ganaha.

Under the concept of “contribute to the medical community and people’s health around the world by expanding awareness of rheumatoid arthritis among the general public as well as patients and their families,” we have decided to release a disease awareness film by means of anime, one of the icons of Japanese culture. With this movie, we aim to appeal to a broad age range, including the younger generation aged between 10 to 29, about the importance of “early detection”, “early treatment” and “medical care provided by rheumatologists”.

Tatsunoko Production Co., Ltd., a company that has introduced Japan’s leading anime series including “Yatterman” and “The Genie Family” throughout the world, was responsible for character design and production. Ayana Taketatsu, a voice actress who has over one million followers on Twitter, and Kayoko Ohkubo, a comedienne who herself has experienced rheumatoid arthritis, voiced the main characters.

Chugai is continuously committed to promoting disease awareness activities leading to trust and appreciation from all stakeholders including patients, their families, and healthcare professionals, aiming at contributing to the medical community and people’s health around the world.

● A Summary of the Rheumatoid Arthritis Awareness Animation

[Title]   Disease Awareness Anime on Rheumatoid Arthritis, “Magic Glasses” (6 minutes and 55 seconds)
[Released on] Videos & Advertisements in Chugai Pharmaceutical’s corporate website

https://www.chugai-pharm.co.jp/english/profile/ad/index.html

Chugai Pharmaceutical’s YouTube official channel

https://www.youtube.com/user/chugaijp

 

[Story]     Nanami and Hikaru have grown up together on an island. They were spending happy and cheerful days. It happened on one of those days when Nanami was a senior in high school. Nanami’s mother started to complain of discomfort of the hands and fingers. Nanami was worried about her mother and took her to a hospital. The symptoms, however, did not improve. Hikaru was determined to become a doctor to help Nanami and her mother suffering from the unexplained symptoms. After becoming a medical student, Hikaru studied hard and encouraged Nanami’s mother to consult a rheumatologist. Nanami was relieved seeing her mother successfully started treatment of rheumatoid arthritis. In fact, Hikaru helped Nanami because he had certain thoughts.
 

[Voice Actors/Actresses (Cast)]

Character   Cast
Nanami Ayana Taketatsu / voice actress, singer, and narrator
Hikaru Miyu Irino / voice actor and singer
Minami Kayoko Ohkubo / comedienne (Oasiz)
Nozomi   Mizuha Kuraoka / pop star (22/7)
 

About Chugai

Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2017 of Chugai totalled 534.2 billion yen and the operating income was 103.2 billion yen (IFRS Core basis).
Additional information is available on the internet at https://www.chugai-pharm.co.jp/english.

Contact information

For Media
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
Tomoko Shimizu
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp
***
For European media
Chugai Pharma France SAS
Nathalie Leroy
Tel: +33-1-56-37-05-21
E-mail: pr@chugai.eu
***
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Susan Chou
Tel: +886-2-2715-2000
E-mail: pr@chugai.com.tw
***
For Investors
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel: +81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Head Position During Sleep Has Potential Implications for Neurodegenerative Disease19.2.2019 17:00:00Tiedote

Could sleeping on your back increase your brain's risk of developing neurodegenerative disease? That possibility is revealed in a new study published in the Journal of Alzheimer's Disease. "We compared the in-home sleep patterns of patients with memory impairment resulting from neurodegenerative diseases to a large group of elderly with normal cognition," stated Daniel J. Levendowski, the study's first author and President of Advanced Brain Monitoring. "Sleeping more than 2 hours with one's head lying face upward (i.e., supine) was a significant nocturnal marker that characterized those with memory impairment, after controlling for factors such as age, sex, snoring, obstructive sleep apnea, and movements during the night." These results corroborate in humans a finding observed in rats by researchers at Stony Brook University and published in the Journal of Neuroscience. Using dynamic contrast MRI, they found that the clearance of neurotoxic proteins from the brain by glymphatic transpo

Ahearn & Soper Finds that ExaGrid Stands Behind Its Scalable System19.2.2019 17:00:00Tiedote

ExaGrid®, a leading provider of intelligent hyperconverged storage for backup, today announced that Ahearn & Soper has optimized and further protected its backup environment by establishing offsite replication using ExaGrid hyperconverged backup with data deduplication, and has been able to match its data growth due to ExaGrid’s scalable architecture. Ahearn & Soper Inc. provides barcode software and hardware solutions that improve accuracy, tracking, and efficiency within distribution, manufacturing, and healthcare operations. The company is headquartered in Toronto, Ontario, and operates across North America from branch sales and service offices. Ahearn & Soper decided to add disaster recovery (DR) to its backup environment and wanted a solution that provided offsite replication. “ExaGrid came to our site and explained how the system worked and the benefits of its architecture. We were quite impressed with the product because of the self-contained nature of the system and how it hand

Airspan Introduces 5G Millimeter Wave RAN Infrastructure Utilizing the Qualcomm FSM100xx 5G Platform19.2.2019 16:36:00Tiedote

Airspan Networks Inc. is excited to announce today that they will be expanding their cooperation with Qualcomm Technologies, Inc., a subsidiary of Qualcomm Incorporated, to include the development of 5G NR mmWave RAN solutions, leveraging the Qualcomm FSM100xx 5G Platform. This comes in the wake of the joint multi-award-winning success in 4G for the Sprint Magic Box and Reliance Jio’s ground-breaking ultra-dense Greenfield network. Airspan has deployed close to half a million small cells worldwide based on the powerful Qualcomm FSM99xx Small Cell Platform, leveraging its advanced feature sets. Airspan has been able to deliver on the promise of 4G small cells to improve indoor and outdoor wireless network capacity and coverage, increasing macro network efficiency and revolutionizing TCO. Airspan is developing 5G RAN solutions, in both Sub-6 GHz and mmWave bands to meet the wide range of challenges experienced today by mobile operators. The products will feature advanced technologies inc

Sartorius Closes Fiscal 2018 Successfully and Aims to Further Expand19.2.2019 16:08:00Tiedote

Sartorius (FWB:SRT), a leading international partner of biopharmaceutical research and the industry, confirmed its preliminary figures with the publication of its 2018 Annual Report. Accordingly, the Group continued on the growth track in both divisions and across all geographies, and thus achieved its forecast raised considerably at mid-year. Group sales revenue rose in constant currencies by 13.2% to 1,566.0 million euros (reported: +11.5%), with the non-organic share of this figure amounting to around one percentage point. The EMEA region (Europe | Middle East | Africa) accounted for 42% of consolidated sales; the Americas, 33%; and Asia | Pacific, 25%. Order intake rose in constant currencies by 12.5% to 1,662.5 million euros. The positive development of the Group is reflected by the organic increase in the number of employees. As at December 31, 2018, a total of 8,125 people were employed at Sartorius worldwide; this was a year-over-year gain of some 600 new employees or 8.3%. “Sa

BOC Group Announces the Release of its Latest BPM Suite: ADONIS NP 6.0 Out Now and Better Than Ever Before!19.2.2019 16:00:00Tiedote

BOC Group has just released the next major version upgrade of its BPM suite ADONIS NP and introduced a great mix of brand new features, enhanced extensions and different technology updates. The new ADONIS NP 6.0 brings meaningful innovation for all users, with a special emphasis on making better decisions faster with the help of Business Process Simulation & Optimization. Providing powerful Process Simulation, the latest release of the Business Transformation Suite ADONIS NP encompasses major new features and cutting-edge capabilities to facilitate, optimize and accelerate digital transformation! It is a step forward into a new era of innovation and simplicity. Tobias Rausch, ADONIS NP product manager says: “Business Process Simulation & Optimization is without a doubt the flagship feature of the new ADONIS NP 6.0. It allows you to visualize, change, slice and dice your processes and test alternatives in a risk-free environment, before taking an actual step change and committing capita

The Company SP3H Announces It Has Entered the Final Phase of Its European VIP Program (Intelligent and Clean Vehicle), Linked to the Pre-Industrialization of Its fluidBOX Infrared Scanners19.2.2019 14:05:00Tiedote

The first orders have already been posted on the car market, in anticipation of the introduction of the new EU legislation on CO 2 emissions target from vehicles in 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190219005456/en/ This success has enabled SP3H to receive the second tranche of € 473k from the EU, thus raising the amount received since October 2017 to € 1M. During the summer of 2017, VIP received the prestigious H2020 label "EIC SME Instrument Phase 2" in the "transport & smart cities mobility" category. With a total budget of 1.7M €, VIP is subsidized by the European Union for 70% or 1.2M€ has enabled SP3H to join the prestigious circle of French winners of the H2020 EIC SME Instrument Phase 1 and 2 programs. VIP is the pre-industrialization program for Fluidbox sensors, the first miniaturized scanner in the world capable of analyzing the quality of fuels in vehicles. The heart of the program remains clos

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme